peg-GCSF
3 abstracts
Abstract
Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.Org: Haeundae Paik Hospital,
Abstract
Comparison of prophylactic effects for chemotherapy-induced neutropenia between same-day vs next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myelosuppressive agent: A randomized phase III trial (CONCISE, KCSG PC22-11).Org: Hanyang University Seoul Hospital, Yangsan, South Korea, Uijeongbu St. Mary’s Hospital, Uijeongbu, South Korea, Dong-A University College of Medicine,
Abstract
Possible advantage of granulocyte colony-stimulating factor in breast cancer chemotherapy during COVID-19 pandemic: A single center experience in Japan.Org: Nagoya Tokushukai General Hospital,